CoLucid names Thomas P. Mathers CEO

Wednesday, July 20, 2011 11:28 AM

CoLucid Pharmaceuticals, a privately held biopharmaceutical company, has named Thomas P. Mathers its chief executive officer.

Mathers has more than 19 years of executive management, sales and marketing experience in the life sciences and medical device industry. He also serves on the board of directors for the Biotechnology Industry Organization (BIO), and as chairman of Declion Pharmaceuticals, a company he co-founded. Previously, he served as president and CEO of Peptimmune.

"Tom will lead the CoLucid team in formulating our phase III development and commercialization plans for lasmiditan," said Art Pappas, chairman of the board of directors and managing partner at Pappas Ventures.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs